Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company’s cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
Latest quote
$64.11
+$0.98 · +1.55%
After-hours
$64.11
$0.00 · 0.00%
Oct 9, 5:34 PM ET
Regular session · ET · Market data may be delayed.
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company’s cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
Day range
Current $64.11
52-week range
Current $64.11
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
74
Undervalued
Sentiment
62
Bullish
Risk
32
Moderate Risk
Momentum
39
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company’s cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
Day range
Current $64.11
52-week range
Current $64.11
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 10.4B USD | 9.91B USD | 9.46B USD | 8.72B USD | 8.29B USD |
| Cost of goods sold | 4.66B USD | 4.4B USD | 4.21B USD | 3.97B USD | 3.64B USD |
| Gross profit | 5.75B USD | 5.51B USD | 5.25B USD | 4.75B USD | 4.65B USD |
| Research and development | 990M USD | 876M USD | 859M USD | 702M USD | 842M USD |
| Selling, general, and administrative | 3.45B USD | 3.25B USD | 3.21B USD | 3.07B USD | 3.08B USD |
| Operating expenses | 4.39B USD | 4.1B USD | 4.21B USD | 4.08B USD | 4.07B USD |
| Interest income | 74M USD | 81.45M USD | 34M USD | 16.52M USD | 3.01M USD |
| Interest expense | 204M USD | 186.18M USD | 189M USD | 138.4M USD | 120.26M USD |
| Depreciation and amortization | 1.34B USD | 1.23B USD | 1.22B USD | 1.12B USD | 1.22B USD |
| Operating income | 1.36B USD | 1.41B USD | 1.04B USD | 672M USD | 580M USD |
| Net income | 980M USD | 1.02B USD | 974M USD | 335M USD | 376M USD |
Company facts updated Oct 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$73.88
15.24% upsideCash distributions grouped by calendar year; partial years are marked.
$0.3334
2025 complete year+203.9% since 2021
2026 partial: $0.3593
$0.1097
2,021
$0.205
2,022
$0.2357
2,023
$0.2647
2,024
$0.3334
2,025
$0.3593
2,026*
* Partial calendar year in the available dividend history.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | May 6, 2026 | $0.3593Annual | May 6, 2026 | May 7, 2026 |
Dividend | May 14, 2025 | $0.3334Annual | May 14, 2025 | May 15, 2025 |
Dividend | May 14, 2024 | $0.2647Annual | May 15, 2024 | May 16, 2024 |
Dividend | May 10, 2023 | $0.2357Annual | May 11, 2023 | May 12, 2023 |
Dividend | May 3, 2022 | $0.205Annual | May 4, 2022 | May 5, 2022 |
Dividend | May 4, 2021 | $0.10Annual | May 5, 2021 | May 6, 2021 |
Ex-dividend May 6, 2026
$0.3593
Annual
Record May 6, 2026 · Payment May 7, 2026
Ex-dividend May 14, 2025
$0.3334
Annual
Record May 14, 2025 · Payment May 15, 2025
Ex-dividend May 14, 2024
$0.2647
Annual
Record May 15, 2024 · Payment May 16, 2024
Ex-dividend May 10, 2023
$0.2357
Annual
Record May 11, 2023 · Payment May 12, 2023
Ex-dividend May 3, 2022
$0.205
Annual
Record May 4, 2022 · Payment May 5, 2022
Ex-dividend May 4, 2021
$0.10
Annual
Record May 5, 2021 · Payment May 6, 2021
Funds reporting this stock among their holdings, ordered by reported position size.
Kovitz Core Equity ETFEQTY39.45M3.06%1.42B USD0.99%$29.445+0.42%
Dimensional - International Value ETFDFIV30.99M0.15%21.39B USD0.27%$55.42+0.25%
Dimensional - International Core Equity Market ETFDFAI17.08M0.10%17.78B USD0.18%$41.34+0.66%
Dimensional - International Core Equity 2 ETFDFIC14.15M0.10%15.02B USD0.22%$37.53+0.64%
Dimensional World ex U.S. Core Equity 2 ETFDFAX7.38M0.06%12.26B USD0.28%$37.08+0.76%
Running Oak Efficient Growth ETFRUNN6.64M1.72%412.23M USD0.58%$33.3034+0.44%
John Hancock Investments - Multifactor Developed International ETFJHMD2.99M0.31%964.94M USD0.39%$44.09+0.52%
Invesco RAFI Developed Markets ex-U.S. ETFPXF2.86M0.10%2.89B USD0.43%$75.89+0.37%
Kovitz Core Equity ETFEQTY
Dimensional - International Value ETFDFIV
Dimensional - International Core Equity Market ETFDFAI
Dimensional - International Core Equity 2 ETFDFIC
Dimensional World ex U.S. Core Equity 2 ETFDFAX
Running Oak Efficient Growth ETFRUNN
John Hancock Investments - Multifactor Developed International ETFJHMD
Invesco RAFI Developed Markets ex-U.S. ETFPXFAI-generated and delayed market data for informational and educational purposes only. Not investment advice.